Niederseer David, Wernly Bernhard, Aigner Elmar, Stickel Felix, Datz Christian
Department of Cardiology, University Heart Center Zurich, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland.
Department of Anaesthesiology, Perioperative Medicine and Intensive Care Medicine, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria.
J Clin Med. 2021 Jan 26;10(3):467. doi: 10.3390/jcm10030467.
Overwhelming evidence suggests an association of cardiovascular disease (CVD) with non-alcoholic fatty liver disease (NAFLD); however, the underlying mechanisms remain largely speculative. It is, however, likely that common mechanisms contribute to the development of CVD and NAFLD, with lifestyle factors such as smoking, sedentary lifestyle with poor nutrition habits and physical inactivity being major candidates. These behavioral factors, on a predisposing genetic background, trigger changes in gut microbiota, inflammation, dyslipidemia and oxidative stress, leading to metabolic syndrome, diabetes and obesity as well as atherosclerosis. Treatment options to counteract both the progression and development of CVD and NAFLD include lifestyle interventions, optimal medical therapy of comorbid conditions and, as final possibility, bariatric surgery. As no causal pharmacotherapy of NAFLD is available, further research is urgently needed to address the unmet need of a growing population with NAFLD and CVD.
大量证据表明心血管疾病（CVD）与非酒精性脂肪性肝病（NAFLD）之间存在关联；然而，其潜在机制在很大程度上仍属推测。不过，很可能有一些共同机制促成了CVD和NAFLD的发展，吸烟、久坐不动且营养习惯不良以及缺乏身体活动等生活方式因素是主要候选因素。在易患基因背景下，这些行为因素会引发肠道微生物群、炎症、血脂异常和氧化应激的变化，导致代谢综合征、糖尿病、肥胖以及动脉粥样硬化。应对CVD和NAFLD进展及发展的治疗选择包括生活方式干预、对合并症的最佳药物治疗，以及最后可能的减肥手术。由于目前尚无针对NAFLD的因果性药物疗法，迫切需要进一步开展研究，以满足日益增多的NAFLD和CVD患者未得到满足的需求。
